NEW YORK (GenomeWeb) – Molecular Health today said it has reached a distribution deal with TestAnalytika covering Latin America.
Under the terms of the agreement, TestAnalytika will provide Molecular Health's TreatmentMAP to patients, physicians, hospitals, laboratories, cancer centers, and insurers in the region later this year.
TreatmentMAP is a next-generation sequencing-based test that generates individualized tumor analysis and provides genomic patient data interpretation for clinical use. Last week, Molecular Health and the Guardian Research Network announced a collaboration using TreatmentMAP to provide US-based cancer patients with access to therapeutic clinical trials and molecular diagnostic decision support.
Based in Houston, TestAnalytika provides US-based, long-distance cancer advisory services, genomic testing, and diagnostic support services to physicians and patients in developing nations, according to its website.
Financing and terms of the deal were not disclosed.